According to our latest study on “Irritable Bowel Syndrome (IBS) Treatment Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Product, and Distribution Channel,” the market was valued at US$ 2,153.89 million in 2020 and is projected to reach US$ 4,600.30 million by 2028; it is expected to grow at a CAGR of 10.1% from 2021 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market.

(**Note: The sample of this report is updated with COVID-19 impact analysis**)
To Know How COVID-19 Pandemic Will Impact Global Irritable Bowel Syndrome (IBS) Treatment Market | Get a Sample Copy of Report, Click Here: 

Based on type, the irritable bowel syndrome (IBS) treatment market is segmented into mixed IBS (IBS-M), IBS with diarrhea (IBS-D), and IBS with constipation (IBS-C). The mixed IBS (IBS-M) segment held the largest share of the market in 2020. Also, the same segment is expected to register the highest CAGR during 2021–2028. In the coming years, the rising prevalence of IBS among women and men is anticipated to propel the demand for the medicines that can treat combined symptoms of constipation and diarrhea. According to updated Rome IV criteria, the reverse condition of IBS-M is described as a model of hard or irregular stools in more than 25% of bowel movements. The prevalence is higher in the geriatric population. Therefore, the demand for medicines to treat mixed IBS is likely to grow significantly during the forecast period,

The growth of the irritable bowel syndrome (IBS) treatment market is primarily attributed to the key driving factors such as increasing IBS diseases prevalence and rising research & development activities. However, the limited number of product availability and treatment inefficiency hinder the market growth. Ironwood Pharmaceuticals, Inc.; AbbVie.; Sebela Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Alfasigma S.p.A.; Astellas Pharma Inc.; AstraZeneca; Synthetic Biologics, Inc.; Bausch + Lomb Incorporated; and Lannett Company Inc are among the leading companies operating in the market.

By Type

  • IBS with Diarrhea (IBS-D)
  • IBS with Constipation (IBS-C)
  • Mixed IBS (IBS-M)

By Product

  • Rifaximin
  • Eluxadoline
  • Linaclotide
  • Lubiprostone
  • Others

By Distribution Channel

  • Hospitals Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
      • US
      • Canada
      • Mexico
  • Europe
      • France
      • Germany
      • UK
      • Spain
      • Italy
      • Rest of Europe
  • Asia Pacific (APAC)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Rest of APAC
  • Middle East and Africa (MEA)
      • Saudi Arabia
      • UAE
      • South Africa
      • Rest of MEA
  • South and Central America (SCAM)
      • Brazil
      • Argentina
      • Rest of SCAM

Purchase a copy of the report

Tags: , , , , , , , , , , , , , , ,

See Campaign:
Contact Information:
Contact Person: Sameer Joshi
Phone: +1-646-491-9876 Email Id:

Menafn, iCN Internal Distribution, Research Newswire, English


Contact Information:

Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: